Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

[1]  D. van Soolingen,et al.  Mapping of IS6110 insertion sites in Mycobacterium bovis isolates in relation to adaptation from the animal to human host. , 2008, Veterinary microbiology.

[2]  S. Cole,et al.  Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoP , 2008, PLoS pathogens.

[3]  I. Smith,et al.  Structure of the DNA-binding domain of the response regulator PhoP from Mycobacterium tuberculosis. , 2007, Biochemistry.

[4]  D. Sarkar,et al.  PhoP-PhoP Interaction at Adjacent PhoP Binding Sites Is Influenced by Protein Phosphorylation , 2007, Journal of bacteriology.

[5]  S. Cole,et al.  A Point Mutation in the Two-Component Regulator PhoP-PhoR Accounts for the Absence of Polyketide-Derived Acyltrehaloses but Not That of Phthiocerol Dimycocerosates in Mycobacterium tuberculosis H37Ra , 2007, Journal of bacteriology.

[6]  Jun Liu,et al.  Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. , 2007, Vaccine.

[7]  Wilbert Bitter,et al.  Type VII secretion — mycobacteria show the way , 2007, Nature Reviews Microbiology.

[8]  Amit Singh,et al.  Mycobacterium tuberculosis WhiB3 responds to O2 and nitric oxide via its [4Fe-4S] cluster and is essential for nutrient starvation survival , 2007, Proceedings of the National Academy of Sciences.

[9]  D. Collins,et al.  A new attenuated Mycobacterium bovis vaccine protects brushtail possums (Trichosurus vulpecula) against experimental tuberculosis infection. , 2007, Vaccine.

[10]  Julian Parkhill,et al.  Genome plasticity of BCG and impact on vaccine efficacy , 2007, Proceedings of the National Academy of Sciences.

[11]  D. Sherman,et al.  Mycobacterial virulence and specialized secretion: same story, different ending , 2007, Nature Medicine.

[12]  S. Zodpey.  Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis. , 2007, Indian journal of dermatology, venereology and leprology.

[13]  Paul D van Helden,et al.  Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions , 2006, BMC Evolutionary Biology.

[14]  David Eisenberg,et al.  A specific secretion system mediates PPE41 transport in pathogenic mycobacteria , 2006, Molecular microbiology.

[15]  D. Sarkar,et al.  Transcriptional autoregulation by Mycobacterium tuberculosis PhoP involves recognition of novel direct repeat sequences in the regulatory region of the promoter , 2006, FEBS letters.

[16]  W. Bishai,et al.  Differential Gene Expression in Response to Exposure to Antimycobacterial Agents and Other Stress Conditions among Seven Mycobacterium tuberculosis whiB-Like Genes , 2006, Antimicrobial Agents and Chemotherapy.

[17]  J. Sadoff,et al.  Advances in tuberculosis vaccine strategies , 2006, Nature Reviews Microbiology.

[18]  E. Gormley,et al.  The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. , 2006, Vaccine.

[19]  Irina Kolesnikova,et al.  The Mycobacterium tuberculosis PhoPR two‐component system regulates genes essential for virulence and complex lipid biosynthesis , 2006, Molecular microbiology.

[20]  M. Horwitz,et al.  A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. , 2006, Vaccine.

[21]  Brigitte Gicquel,et al.  The Virulence-associated Two-component PhoP-PhoR System Controls the Biosynthesis of Polyketide-derived Lipids in Mycobacterium tuberculosis* , 2006, Journal of Biological Chemistry.

[22]  J. Norton,et al.  Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Bonah.  The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933. , 2005, Studies in history and philosophy of biological and biomedical sciences.

[24]  Juan Zurita,et al.  The dimycocerosate ester polyketide virulence factors of mycobacteria. , 2005, Progress in lipid research.

[25]  M. Horwitz,et al.  Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein , 2005, Infection and Immunity.

[26]  G. Besra,et al.  Transposon Mutagenesis of Mb0100 at the ppe1-nrp Locus in Mycobacterium bovis Disrupts Phthiocerol Dimycocerosate (PDIM) and Glycosylphenol-PDIM Biosynthesis, Producing an Avirulent Strain with Vaccine Properties At Least Equal to Those of M. bovis BCG , 2005, Journal of bacteriology.

[27]  S. Cole,et al.  Differential Effects of Prior Exposure to Environmental Mycobacteria on Vaccination with Mycobacterium bovis BCG or a Recombinant BCG Strain Expressing RD1 Antigens , 2005, Infection and Immunity.

[28]  M. Reed,et al.  A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response , 2004, Nature.

[29]  Jude W. Shavlik,et al.  A self-tuning method for one-chip SNP identification , 2004, Proceedings. 2004 IEEE Computational Systems Bioinformatics Conference, 2004. CSB 2004..

[30]  I. Knezevic,et al.  Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. , 2004, Vaccine.

[31]  Christopher W. Wong,et al.  Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. , 2004, Genome research.

[32]  C. Soto,et al.  IS6110 Mediates Increased Transcription of the phoP Virulence Gene in a Multidrug-Resistant Clinical Isolate Responsible for Tuberculosis Outbreaks , 2004, Journal of Clinical Microbiology.

[33]  M. Behr,et al.  The in vitro evolution of BCG vaccines. , 2003, Vaccine.

[34]  Julian Parkhill,et al.  The complete genome sequence of Mycobacterium bovis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Cole,et al.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis , 2003, Nature Medicine.

[36]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[37]  T. Richmond,et al.  Light-directed 5'-->3' synthesis of complex oligonucleotide microarrays. , 2003, Nucleic acids research.

[38]  Tanya Parish,et al.  Deletion of Two-Component Regulatory Systems Increases the Virulence of Mycobacterium tuberculosis , 2003, Infection and Immunity.

[39]  Franco Cerrina,et al.  Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. , 2002, Genome research.

[40]  W. Jacobs,et al.  Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Behr.  BCG--different strains, different vaccines? , 2002, The Lancet. Infectious diseases.

[42]  R. Appelberg,et al.  Failure of the Mycobacterium bovis BCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to Tuberculosis , 2002, Infection and Immunity.

[43]  M. Horwitz,et al.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Gingeras,et al.  Detection of deleted genomic DNA using a semiautomated computational analysis of GeneChip data. , 2000, Genome research.

[45]  T. Brewer.  Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  C. Buchrieser,et al.  Comparative Genomics Uncovers Large Tandem Chromosomal Duplications in Mycobacterium Bovis BCG Pasteur , 2000, Yeast.

[47]  William R. Jacobs,et al.  Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice , 1999, Nature.

[48]  K. Hasløv,et al.  Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. , 1999, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[49]  E. Gormley,et al.  A novel polymorphic genetic locus in members of the Mycobacterium tuberculosis complex. , 1999, Microbiology.

[50]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[51]  M. Behr,et al.  A historical and molecular phylogeny of BCG strains. , 1999, Vaccine.

[52]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[53]  S. Cole,et al.  Physical mapping of Mycobacterium bovis BCG pasteur reveals differences from the genome map of Mycobacterium tuberculosis H37Rv and from M. bovis. , 1996, Microbiology.

[54]  G. Mahairas,et al.  Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis , 1996, Journal of bacteriology.

[55]  C. Leclerc,et al.  Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains , 1996, Infection and immunity.

[56]  C S Berkey,et al.  The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. , 1995, Pediatrics.

[57]  M. Horwitz,et al.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[58]  G. Comstock.  Field trials of tuberculosis vaccines: how could we have done them better? , 1994, Controlled clinical trials.

[59]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[60]  J. W. Dale,et al.  Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. , 1992, The Journal of applied bacteriology.

[61]  P. Mihăilescu,et al.  Second IUATLD study on complications induced by intradermal BCG-vaccination. , 1988, Bulletin of the International Union against Tuberculosis and Lung Disease.

[62]  A. Lind.  The Swedish strain of BCG. , 1983, Tubercle.

[63]  T. Osborn.  Changes in BCG strains. , 1983, Tubercle.

[64]  B. Gicquel,et al.  Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials , 2008, Expert opinion on biological therapy.

[65]  조상래,et al.  Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. , 2008 .

[66]  J. Stockman.  Effect of BCG Vaccination on Childhood Tuberculous Meningitis and Miliary Tuberculosis Worldwide: A Meta-analysis and Assessment of Cost-effectiveness , 2007 .

[67]  BCG vaccine. WHO position paper. , 2004, Releve epidemiologique hebdomadaire.

[68]  C. Martín,et al.  High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  G. Colditz,et al.  Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  J. Gibson,et al.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. , 1990, Bulletin of the World Health Organization.

[71]  O. Wasz‐Höckert,et al.  BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. , 1984, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.

[72]  J. Guld,et al.  Tuberculin sensitivity in guinea-pigs after vaccination with varying doses of BCG of 12 different strains. , 1976, Bulletin of the World Health Organization.

[73]  H. Mohelská,et al.  Some biological, biochemical and morphological changes and their correlations in selected BCG vaccine strains. , 1976, Journal of Biological Standardization.

[74]  K. Gupta.  Effect of freeze-drying on the colony morphology of various daughter strains of BCG. , 1975, Journal of Biological Standardization.

[75]  R. S. Vallishayee,et al.  Tuberculin sensitivity and skin lesions in children after vaccination with 11 different BCG strains. , 1974, Bulletin of the World Health Organization.